Download PDF

Register to download the report. Already a member?

Sign Up


71112 1524142686HCLSReviewBalticsApril2018.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:


Peter Tsai – Founder, CEO & Chairman, Orient EuroPharma (OEP) & Orient Pharma (OP), Taiwan

UntitledPeter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s revenues within the next five years and nurture the long-term growth of the company he founded in 1982, while OEP’s activities now encompass drug development, small-molecule manufacturing, as well as OEP’s historical leadership in the distribution of specialty products across Southeast Asia.

At the moment, many leading historical groups of pharmaceutical companies in Taiwan seem to be shifting their strategic focus to enter the new drug development area and/or increase their international footprint, what is the vision driving the development of Orient EuroPharma?

I set up Orient Europharma (OEP) in 1982 as a distributor for France’s Rhône-Poulenc. Given that for the first few years we were successful, I started to diversify the company’s client base, entering talks with Hoechst and Elan. However, the strategy changed when these big European pharmaceutical giants began merging with one another, and we started to license in products from European companies such as Italy-headquartered Chiesi and Recordati or France’s Pierre Fabre, for whom we are the regional distributor serving Singapore, Malaysia, Hong Kong, and Taiwan, but also partnering with Almirall and Pfizer – among many others.



Most Read

Download PDF

First Name:

Last Name: